Adherence to preventive statin therapy according to socioeconomic position

European Journal of Clinical Pharmacology

Volumn 69, Issue 8, 2013, Pages 1553-1563

  Wallach Kildemoes, Helle ^c   Andersen, Morten ^a,b   Diderichsen, Finn ^c   Lange, Theis ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adherence; High risk strategy; Primary prevention; Socioeconomic differences; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FEMALE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVENTIVE MEDICINE; PRIMARY PREVENTION; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIAL STATUS;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; EDUCATIONAL STATUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SEX CHARACTERISTICS; SOCIOECONOMIC FACTORS;

EID: 84880510480     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1488-6     Document Type: Article

References (71)

1. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383-1389
2. Ong HT (2005) The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 98(8):599-614
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 24(17):1601-1610
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 194(1):1-45
5. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24(11):987-1003
6. Brindle P, Beswick A, Fahey T, Ebrahim S (2006) Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92(12):1752-1759
7. Abramson J, Wright JM (2007) Are lipid-lowering guidelines evidence-based? Lancet 369(9557):168-169
8. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159(9):882-890
9. Wallach Kildemoes H, Diderichsen F, Krasnik A, Lange T, Andersen M (2012) Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study. BMC Publ Health 12(1):610
10. Getz L, Sigurdsson JA, Hetlevik I (2003) Is opportunistic disease prevention in the consultation ethically justifiable? BMJ 327(7413):498-500
11. McElduff P, Jaefarnezhad M, Durrington PN (2006) American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively. Heart 92(9):1213-1218
12. Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL (2003) Primary care: is there enough time for prevention? Am J Public Health 93(4):635-641
13. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM et al (2006) Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ 332(7555):1419
14. Brugts JJ, Deckers JW (2010) Statin prescription in men and women at cardiovascular risk: to whom and when? Curr Opin Cardiol 25(4):484-489
15. Getz L, Sigurdsson JA, Hetlevik I, Kirkengen AL, Romundstad S, Holmen J (2005) Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. BMJ 331(7516):551
16. Lynch J, Davey SG, Harper S, Bainbridge K (2006) Explaining the social gradient in coronary heart disease: comparing relative and absolute risk approaches. J Epidemiol Community Health 60(5):436-441
17. Marmot MG, Smith GD, Stansfeld S, Patel C, North F, Head J et al (1991) Health inequalities among British civil servants: the Whitehall II study. Lancet 337(8754):1387-1393
18. Mackenbach JP, Bos V, Andersen O, Cardano M, Costa G, Harding S et al (2003) Widening socioeconomic inequalities in mortality in six Western European countries. Int J Epidemiol 32(5):830-837
19. Capewell S (2008) Will screening individuals at high risk of cardiovascular events deliver large benefits? No. BMJ 337:a1395
20. Rose G (1992) The strategy of preventive medicine. Oxford University Press, Oxford
21. Sigurdsson EL, Thorgeirsson G (2003) Primary prevention of cardiovascular diseases. Scand J Prim Health Care 21(2):68-74
22. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S (2004) Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 25(6):484-491
23. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A et al (2006) Revisiting Rose: strategies for reducing coronary heart disease. BMJ 332(7542):659-662
24. Marmot M, Friel S, Bell R, Houweling TA, Taylor S (2008) Closing the gap in a generation: health equity through action on the social determinants of health. Lancet 372(9650):1661-1669
25. Atkinson T (2002) Social inclusion and the European Union. J Common Market Stud 40(4):625-643
26. Wallach Kildemoes H, Hendriksen C, Andersen M (2012) Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemiol Drug Saf 21(10):1027-1035
27. Bouchard MH, Dragomir A, Blais L, Berard A, Pilon D, Perreault S (2007) Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 63(6):698-708
28. Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C et al (2005) Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol 61(9):667-674
29. Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L et al (2005) Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 59(5):564-573
30. Bates TR, Connaughton VM, Watts GF (2009) Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 10(18):2973-2985
31. Larsen J, Andersen M, Kragstrup J, Gram LF (2002) High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol 53(4):375-378
32. Poluzzi E, Strahinja P, Lanzoni M, Vargiu A, Silvani MC, Motola D et al (2008) Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 64(4):425-432
33. Rasmussen JN, Gislason GH, Rasmussen S, Abildstrom SZ, Schramm TK, Kober L et al (2007) Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Commun Health 61(12):1091-1097
34. Hanley GE, Morgan S, Reid RJ (2011) Income-related inequity in initiation of evidence-based therapies among patients with acute myocardial infarction. J Gen Intern Med 26(11):1329-1335
35. Hempler NF, Diderichsen F, Larsen FB, Ladelund S, Jorgensen T (2010) Do immigrants from Turkey, Pakistan and Yugoslavia receive adequate medical treatment with beta-blockers and statins after acute myocardial infarction compared with Danish-born residents? A register-based follow-up study. Eur J Clin Pharmacol 66(7):735-742
36. Sanchez-Ramirez DC, Krasnik A, Kildemoes HW (2013) Do immigrants from Turkey, Pakistan and Ex-Yugoslavia with newly diagnosed type 2 diabetes initiate recommended statin therapy to the same extent as Danish-born residents? A nationwide register study. Eur J Clin Pharmacol 69(1):87-95
37. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM (2004) Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 19(6):638-645
38. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ (2007) Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation 115(16):2128-2135
39. Thygesen LC, Daasnes C, Thaulow I, Bronnum-Hansen H (2011) Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation and archiving. Scand J Public Health 39 Suppl 7:12-16
40. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish national prescription registry. Scand J Public Health 39 Suppl 7:38-41
41. WHO Collaborating centre for Drug Statistics Methodology (2010) Guidelines for ATC classification and DDD assignment. Norwegian Institute of Public Health, Oslo
42. Gardarsdottir H, Souverein PC, Egberts TC, Heerdink ER (2010) Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol 63(4):422-427
43. Lynge E, Sandegaard JL, Rebolj M (2011) The Danish national patient register. Scand J Public Health 39[7 Suppl]:30-33
44. Lesen E, Sandstrom TZ, Carlsten A, Jonsson AK, Mardby AC, Sundell KA (2011) A comparison of two methods for estimating refill adherence to statins in Sweden: the RARE project. Pharmacoepidemiol Drug Saf 20(10):1073-1079
45. Nielsen LH, Lokkegaard E, Andreasen AH, Keiding N (2008) Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. Pharmacoepidemiol Drug Saf 17(4):384-388
46. Kildemoes HW, Støvring H, Andersen M (2008) Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model. Br J Clin Pharmacol 66(6):885-895
47. Ruokoniemi P, Korhonen MJ, Helin-Salmivaara A, Lavikainen P, Jula A, Junnila SY et al (2011) Statin adherence and the risk of major coronary events in patients with diabetes: a nested case-control study. Br J Clin Pharmacol 71(5):766-776
48. Kemp A, Roughead E, Preen D, Glover J, Semmens J (2010) Determinants of self-reported medicine underuse due to cost: a comparison of seven countries. J Health Serv Res Policy 15(2):106-114
49. Law MR, Cheng L, Dhalla IA, Heard D, Morgan SG (2012) The effect of cost on adherence to prescription medications in Canada. CMAJ 184(3):297-302
50. Olejaz M, Juul NA, Rudkjobing A, Okkels BH, Krasnik A, Hernandez-Quevedo C (2012) Denmark health system review. Health Syst Transit 14(2):I-192
51. Pedersen KM (2003) Pricing and reimbursement of drugs in Denmark. Eur J Health Econom 4:60-65
52. Thiebaud P, Patel BV, Nichol MB (2008) The demand for statin: the effect of copay on utilization and compliance. Health Econ 17(1):83-97
53. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA (2006) Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care 12(Spec no):SP11-SP19
54. Ye X, Gross CR, Schommer J, Cline R, St Peter WL (2007) Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther 29(12):2748-2757
55. Thomson S, Mossialos E (2004) Influencing demand for drugs through cost sharing. In: Mossialos E, Mrazek M, Walley T (eds) Regulating pharmaceuticals in Europe: Striving for efficiency, equity and quality. Open University Press, Berkshire, pp 227-246
56. Marmot M (2002) The influence of income on health: views of an epidemiologist. Health Aff (Millwood) 21(2):31-46
57. Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Shrank W et al (2007) Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 167(8):847-852
58. Benner JS, Tierce JC, Ballantyne CM, Prasad C, Bullano MF, Willey VJ et al (2004) Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. PharmacoEconomics 22[Suppl 3]:13-23
59. Corrao G, Scotti L, Zambon A, Baio G, Nicotra F, Conti V et al (2011) Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. Atherosclerosis 217(2):479-485
60. Mauskop A, Borden WB (2011) Predictors of statin adherence. Curr Cardiol Rep 13(6):553-558
61. Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J et al (2010) Patient, physician, and payment predictors of statin adherence. Med Care 48(3):196-202
62. Hvelplund A, Galatius S, Madsen M, Sorensen R, Madsen JK, Iversen AZ et al (2012) Significance of the invasive strategy after acute myocardial infarction on prognosis and secondary preventive medication: a nationwide study of 6364 women and 11,915 men. J Invasive Cardiol 24(1):19-24
63. Vaidya V, Partha G, Karmakar M (2012) Gender differences in utilization of preventive care services in the United States. J Womens Health (Larchmt) 21(2):140-145
64. Simpson RJ Jr, Mendys P (2010) The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol 4(6):462-471
65. Andersohn F, Willich SN (2009) The healthy adherer effect. Arch Intern Med 169(17):1635-1636
66. Shrank WH, Patrick AR, Brookhart MA (2011) Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 26(5):546-550
67. Tziomalos K, Athyros VG, Mikhailidis DP (2008) Statin discontinuation: an underestimated risk? Curr Med Res Opin 24(11):3059-3062
68. Schouten O, Hoeks SE, Welten GM, Davignon J, Kastelein JJ, Vidakovic R et al (2007) Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol 100(2):316-320
69. Pineda A, Cubeddu LX (2011) Statin rebound or withdrawal syndrome: does it exist? Curr Atheroscler Rep 13(1):23-30
70. Gomez Sandoval YH, Braganza MV, Daskalopoulou SS (2011) Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des 17(33):3669-3689
71. Støvring H, Harmsen CG, Wisloff T, Jarbol DE, Nexoe J, Nielsen JB et al (2012) A competing risk approach for the European Heart SCORE model based on cause-specific and all-cause mortality. Eur J Prev Cardiol. doi: 10.1177/2047487312445425